| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 571 | 2014 |
| International prognostic scoring system for Waldenström macroglobulinemia P Morel, A Duhamel, P Gobbi, MA Dimopoulos, MV Dhodapkar, J McCoy, ... Blood 113 (18), 4163-4170, 2009 | 316 | 2009 |
| The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance P Maiso, X Carvajal-Vergara, EM Ocio, R López-Pérez, G Mateo, ... Cancer research 66 (11), 5781-5789, 2006 | 257 | 2006 |
| The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes S Tabera, JA Pérez-Simón, M Díez-Campelo, LI Sánchez-Abarca, ... haematologica 93 (9), 1301-1309, 2008 | 251 | 2008 |
| Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia MA Dimopoulos, MA Gertz, E Kastritis, R Garcia-Sanz, EK Kimby, ... J Clin Oncol 27 (1), 120-126, 2009 | 226 | 2009 |
| New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, ... Leukemia 28 (3), 525, 2014 | 210 | 2014 |
| MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia C Jiménez, E Sebastián, MC Chillón, P Giraldo, JM Hernandez, ... Leukemia 27 (8), 1722, 2013 | 191 | 2013 |
| Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic … NC Gutierrez, EM Ocio, J de Las Rivas, P Maiso, M Delgado, E Ferminan, ... Leukemia 21 (3), 541, 2007 | 187 | 2007 |
| Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia SP Treon, MA Gertz, M Dimopoulos, A Anagnostopoulos, J Blade, ... Blood 107 (9), 3442-3446, 2006 | 174 | 2006 |
| Immunophenotypic analysis of Waldenstrom's macroglobulinemia JF San Miguel, MB Vidriales, E Ocio, G Mateo, F Sanchez-Guijo, ... Seminars in oncology 30 (2), 187-195, 2003 | 172 | 2003 |
| Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop RG Owen, RA Kyle, MJ Stone, AC Rawstron, V Leblond, G Merlini, ... British journal of haematology 160 (2), 171-176, 2013 | 150 | 2013 |
| In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma EM Ocio, D Vilanova, P Atadja, P Maiso, E Crusoe, D Fernández-Lázaro, ... haematologica 95 (5), 794-803, 2010 | 147 | 2010 |
| New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings EM Ocio, MV Mateos, P Maiso, A Pandiella, JF San-Miguel The lancet oncology 9 (12), 1157-1165, 2008 | 145 | 2008 |
| JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human … T Kiziltepe, T Hideshima, K Ishitsuka, EM Ocio, N Raje, L Catley, CQ Li, ... Blood 110 (2), 709-718, 2007 | 145 | 2007 |
| 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and … T Kiziltepe, T Hideshima, L Catley, N Raje, H Yasui, N Shiraishi, Y Okawa, ... Molecular cancer therapeutics 6 (6), 1718-1727, 2007 | 138 | 2007 |
| Update on recommendations for assessing response from the Third International Workshop on Waldenström's Macroglobulinemia E Kimby, SP Treon, A Anagnostopoulos, M Dimopoulos, R Garcia-Sanz, ... Clinical Lymphoma and Myeloma 6 (5), 380-383, 2006 | 124 | 2006 |
| MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts S Vallet, N Raje, K Ishitsuka, T Hideshima, K Podar, S Chhetri, S Pozzi, ... Blood 110 (10), 3744-3752, 2007 | 118 | 2007 |
| Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells T Hideshima, L Catley, N Raje, D Chauhan, K Podar, C Mitsiades, YT Tai, ... British journal of haematology 138 (6), 783-791, 2007 | 112 | 2007 |
| Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival MV Mateos, R García‐Sanz, R López‐Pérez, MJ Moro, E Ocio, ... British journal of haematology 118 (4), 1034-1040, 2002 | 106 | 2002 |
| 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis EM Ocio, RFJ Schop, B Gonzalez, SA Van Wier, JM Hernandez‐Rivas, ... British journal of haematology 136 (1), 80-86, 2007 | 105 | 2007 |
